Citations 2
Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.
Sekulić, Aleksandar , Hainsworth, John D. , Lewis, Karl D. , Oro, Anthony E. , Gesierich, Anja , Bernard, Stephen A. , Dréno, Brigitte , Williams, Sarah, Hou, Jeannie , Fisher, David C. , Mortier, Laurent , Dirix, Luc , Murrell, D F , Hauschild, Axel
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9081-9081
Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Lewis, Karl D. , Sekulić, Aleksandar , Migden, Michael R. , Oro, Anthony E. , LoRusso, Patricia , Hainsworth, John D. , Williams, Sarah, Hou, Jeannie , Hoff, Daniel D. Von , Hauschild, Axel , Rudin, Charles M. , Dirix, Luc , Solomon, James A.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9012-9012